Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 56

1.

The Effectiveness and Value of Siponimod for Secondary Progressive Multiple Sclerosis.

Synnott PG, Bloudek LM, Sharaf R, Carlson JJ, Pearson SD.

J Manag Care Spec Pharm. 2020 Mar;26(3):236-239. doi: 10.18553/jmcp.2020.26.3.236.

2.

Cost-effectiveness analysis of low-dose direct oral anticoagulant (DOAC) for the prevention of cancer-associated thrombosis in the United States.

Li A, Carlson JJ, Kuderer NM, Schaefer JK, Li S, Garcia DA, Khorana AA, Carrier M, Lyman GH.

Cancer. 2020 Jan 30. doi: 10.1002/cncr.32724. [Epub ahead of print]

PMID:
31999844
3.

Influence of Modeling Choices on Value of Information Analysis: An Empirical Analysis from a Real-World Experiment.

Kim DD, Guzauskas GF, Bennette CS, Basu A, Veenstra DL, Ramsey SD, Carlson JJ.

Pharmacoeconomics. 2020 Feb;38(2):171-179. doi: 10.1007/s40273-019-00848-8.

PMID:
31631254
4.

Are There Different Evidence Thresholds for Genomic Versus Clinical Precision Medicine? A Value of Information-Based Framework Applied to Antiplatelet Drug Therapy.

Guzauskas GF, Basu A, Carlson JJ, Veenstra DL.

Value Health. 2019 Sep;22(9):988-994. doi: 10.1016/j.jval.2019.03.023. Epub 2019 Aug 1.

PMID:
31511188
5.

Demand for Precision Medicine: A Discrete-Choice Experiment and External Validation Study.

Regier DA, Veenstra DL, Basu A, Carlson JJ.

Pharmacoeconomics. 2020 Jan;38(1):57-68. doi: 10.1007/s40273-019-00834-0.

PMID:
31489595
6.

Achieving Appropriate Model Transparency: Challenges and Potential Solutions for Making Value-Based Decisions in the United States.

Carlson JJ, Walton SM, Basu A, Chapman RH, Campbell JD, McQueen RB, Pearson SD, Touchette DR, Veenstra D, Whittington MD, Ollendorf DA.

Pharmacoeconomics. 2019 Nov;37(11):1321-1327. doi: 10.1007/s40273-019-00832-2.

7.

Competing biomedical HIV prevention strategies: potential cost-effectiveness of HIV vaccines and PrEP in Seattle, WA.

Adamson B, Garrison L, Barnabas RV, Carlson JJ, Kublin J, Dimitrov D.

J Int AIDS Soc. 2019 Aug;22(8):e25373. doi: 10.1002/jia2.25373.

8.

Defining and Managing High-Priced Cures: Healthcare Payers' Opinions.

Yeung K, Suh K, Garrison LP Jr, Carlson JJ.

Value Health. 2019 Jun;22(6):648-655. doi: 10.1016/j.jval.2018.11.012. Epub 2019 May 17.

PMID:
31198181
9.

The Cost-Effectiveness of Financial Incentives for Viral Suppression: HPTN 065 Study.

Adamson B, El-Sadr W, Dimitrov D, Gamble T, Beauchamp G, Carlson JJ, Garrison L Jr, Donnell D.

Value Health. 2019 Feb;22(2):194-202. doi: 10.1016/j.jval.2018.09.001. Epub 2018 Nov 2.

10.

How can clinical researchers quantify the value of their proposed comparative research?

Basu A, Veenstra DL, Carlson JJ, Wang WJ, Branch K, Probstfield J.

Am Heart J. 2019 Mar;209:116-125. doi: 10.1016/j.ahj.2018.12.003. Epub 2018 Dec 8. No abstract available.

PMID:
30638543
11.

Disease-Modifying Therapies for Relapsing-Remitting and Primary Progressive Multiple Sclerosis: A Cost-Utility Analysis.

Zimmermann M, Brouwer E, Tice JA, Seidner M, Loos AM, Liu S, Chapman RH, Kumar V, Carlson JJ.

CNS Drugs. 2018 Dec;32(12):1145-1157. doi: 10.1007/s40263-018-0566-9.

PMID:
30141001
12.

Integrating value of research into NCI Clinical Trials Cooperative Group research review and prioritization: A pilot study.

Carlson JJ, Kim DD, Guzauskas GF, Bennette CS, Veenstra DL, Basu A, Hendrix N, Hershman DL, Baker L, Ramsey SD.

Cancer Med. 2018 Sep;7(9):4251-4260. doi: 10.1002/cam4.1657. Epub 2018 Jul 20.

13.

The Authors Respond: Reframing the Value of Treatments for Relapsed Refractory Multiple Myeloma.

Carlson JJ, Guzauskas GF, Chapman RH, Synnott PG, Liu S, Russo ET, Pearson SD, Brouwer ED, Ollendorf DA.

J Manag Care Spec Pharm. 2018 Jul;24(7):712-713. doi: 10.18553/jmcp.2018.24.7.712.

14.

Cost-savings for biosimilars in the United States: a theoretical framework and budget impact case study application using filgrastim.

Grewal S, Ramsey S, Balu S, Carlson JJ.

Expert Rev Pharmacoecon Outcomes Res. 2018 Aug;18(4):447-454. doi: 10.1080/14737167.2018.1476142. Epub 2018 May 18.

PMID:
29757040
15.

Cost Effectiveness of Alectinib vs. Crizotinib in First-Line Anaplastic Lymphoma Kinase-Positive Advanced Non-Small-Cell Lung Cancer.

Carlson JJ, Suh K, Orfanos P, Wong W.

Pharmacoeconomics. 2018 Apr;36(4):495-504. doi: 10.1007/s40273-018-0625-6.

PMID:
29488070
16.

Cost-effectiveness of Drugs to Treat Relapsed/Refractory Multiple Myeloma in the United States.

Carlson JJ, Guzauskas GF, Chapman RH, Synnott PG, Liu S, Russo ET, Pearson SD, Brouwer ED, Ollendorf DA.

J Manag Care Spec Pharm. 2018 Jan;24(1):29-38. doi: 10.18553/jmcp.2018.24.1.29.

17.

Using Performance-Based Risk-Sharing Arrangements to Address Uncertainty in Indication-Based Pricing.

Yeung K, Li M, Carlson JJ.

J Manag Care Spec Pharm. 2017 Oct;23(10):1010-1015. doi: 10.18553/jmcp.2017.23.10.1010.

18.

Paying for Cures: How Can We Afford It? Managed Care Pharmacy Stakeholder Perceptions of Policy Options to Address Affordability of Prescription Drugs.

Yeung K, Suh K, Basu A, Garrison LP, Bansal A, Carlson JJ.

J Manag Care Spec Pharm. 2017 Oct;23(10):1084-1090. doi: 10.18553/jmcp.2017.23.10.1084.

19.

Favorable and publicly funded studies are more likely to be published: a systematic review and meta-analysis.

Canestaro WJ, Hendrix N, Bansal A, Sullivan SD, Devine EB, Carlson JJ.

J Clin Epidemiol. 2017 Dec;92:58-68. doi: 10.1016/j.jclinepi.2017.08.004. Epub 2017 Aug 31. Review.

PMID:
28842289
20.

Performance-Based Risk-Sharing Arrangements: An Updated International Review.

Carlson JJ, Chen S, Garrison LP Jr.

Pharmacoeconomics. 2017 Oct;35(10):1063-1072. doi: 10.1007/s40273-017-0535-z. Review.

PMID:
28695544

Supplemental Content

Loading ...
Support Center